Bioequivalence Study of Fosinopril Sodium/ Hydrochlorothiazide 20/ 12.5 mg Tablets Under Fasting Conditions
Status:
Completed
Trial end date:
2003-04-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to compare the relative bioavailability of Fosinopril sodium
and hydrochlorothiazide 20-12.5 mg tablets by Ranbaxy Laboratories Limited with that of
Monopril ®.-HCT 20-12.5 mg tablets by Bristol-Meyers Squibb following a single oral dose (1 x
20-12.5 mg tablet) in healthy adult subjects under fasting conditions